193 related articles for article (PubMed ID: 38648056)
41. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
42. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
[TBL] [Abstract][Full Text] [Related]
43. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
44. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
[TBL] [Abstract][Full Text] [Related]
45. Homologous Recombination Deficiencies and Hereditary Tumors.
Yamamoto H; Hirasawa A
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008774
[TBL] [Abstract][Full Text] [Related]
46. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M; Ratajska M; Kozlowski P
J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
[TBL] [Abstract][Full Text] [Related]
47. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination.
Setton J; Selenica P; Mukherjee S; Shah R; Pecorari I; McMillan B; Pei IX; Kemel Y; Ceyhan-Birsoy O; Sheehan M; Tkachuk K; Brown DN; Zhang L; Cadoo K; Powell S; Weigelt B; Robson M; Riaz N; Offit K; Reis-Filho JS; Mandelker D
NPJ Breast Cancer; 2021 Oct; 7(1):135. PubMed ID: 34635660
[TBL] [Abstract][Full Text] [Related]
48. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
49. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
[TBL] [Abstract][Full Text] [Related]
50. Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway.
Szybowska M; Mete O; Weber E; Silver J; Kim RH
Endocr Pathol; 2019 Sep; 30(3):237-245. PubMed ID: 30772928
[TBL] [Abstract][Full Text] [Related]
51. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
52. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
[TBL] [Abstract][Full Text] [Related]
53. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
54. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
[TBL] [Abstract][Full Text] [Related]
55. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
de Jonge MM; Auguste A; van Wijk LM; Schouten PC; Meijers M; Ter Haar NT; Smit VTHBM; Nout RA; Glaire MA; Church DN; Vrieling H; Job B; Boursin Y; de Kroon CD; Rouleau E; Leary A; Vreeswijk MPG; Bosse T
Clin Cancer Res; 2019 Feb; 25(3):1087-1097. PubMed ID: 30413523
[TBL] [Abstract][Full Text] [Related]
56. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
57. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
58. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
59. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
60. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]